09-08-2025
Wolfe Research Sticks to Its Buy Rating for Sotera Health (SHC)
In a report released today, Michael Polark from Wolfe Research maintained a Buy rating on Sotera Health, with a price target of $17.00. The company's shares closed today at $13.97.
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Polark is a 4-star analyst with an average return of 6.5% and a 50.31% success rate. Polark covers the Healthcare sector, focusing on stocks such as Insulet, Medtronic, and Steris.
In addition to Wolfe Research, Sotera Health also received a Buy from Barclays's Luke Sergott in a report issued today. However, on August 1, TR | OpenAI – 4o reiterated a Hold rating on Sotera Health (NASDAQ: SHC).
Based on Sotera Health's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $254.52 million and a GAAP net loss of $13.26 million. In comparison, last year the company earned a revenue of $248.18 million and had a net profit of $6.32 million
